Advertisement

Spotlight Series on Hepatitis C

News

Using Ledipasvir and Sofosbuvir When Prior Treatment With Sofosbuvir Failed

April 2015

In the time before ledipasvir was available, clinical trials with sofosbuvir-based regimens (such as sofosbuvir + ribavirin, or sofosbuvir + interferon + ribavirin) resulted in generally high rates of SVR12. However, there have been cases where HCV was not cured in people who used those sofosbuvir-containing regimens.

Researchers enrolled 51 people who were not cured with sofosbuvir-based regimens and retreated them with the potent combination of ledipasvir + sofosbuvir for 12 weeks.

The average profile of participants at the start of the study was as follows:

  • 61% men and 39% women
  • age -- 54 years
  • HCV genotype 1a -- 59%
  • HCV viral load -- 6.2 log


Results

Out of 51 participants, 50 (98%) developed an SVR12.

In one participant who relapsed, technicians discovered HCV genotype 3a infection.  Ledipasvir + sofosbuvir are not highly effective against this strain of HCV.


Reference

Wyles DL, Pockros PJ, Yang JC, et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract 235.




This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.